Accessibility Menu
Biote logo

Biote(NASDAQ) BTMD

Market Cap$70.67MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2021)-77%
5 Year-76%
1 Year-46%
1 Month+30%
$2.34
+0.43%
+0.01Today
Biote last closing stock price
MetricPriceDate
Last closeUSD 2.332026-07-27
Biote stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-6.43%USD 2.492026-07-20
1 month+30.17%USD 1.792026-06-26
3 month+3.56%USD 2.252026-04-28
Year to date-10.38%USD 2.602025-12-31
1 year-46.06%USD 4.322025-07-25
3 year-66.62%USD 6.982023-07-28
5 year-75.88%USD 9.662021-07-28
Since inception-76.82%USD 10.052021-04-28

Biote Financials at a Glance

Market Cap

$70.67MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$188.16M

Net Income (TTM)

$15.60M

EPS (TTM)

$0.45

P/E Ratio

5.18

Dividend

$0.00

Beta (Volatility)

0.55 (Low)

Price

$2.34

Volume

20

Open

$2.34

Previous Close

$2.33

Daily Range

$2.34 - $2.34

52-Week Range

$1.27 - $4.75

Estimated Earnings Date

Aug 5, 2026

BTMD News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Biote

biote helps people manage hormone and vitamin imbalances through certified clinics. Its platform supports doctors with training and tools for hormone therapy. Patients benefit from tailored treatments and supplements for everyday health needs.

Products and Services

  • Hormone Optimization Platform: Practice-building tools and training for clinics; 71% of 2025 revenue.
  • Bioidentical Hormone Pellets: Hormone therapy for men and women; used in certified clinics.
  • Biote-branded Supplements: 26 dietary supplements for hormone, vitamin, and mineral support; 22% of 2025 revenue.
  • Sterile Pellet Insertion Kits: Kits for in-office hormone pellet procedures; sold to clinics.
  • Practice Management Software: Inventory and compliance tools for clinics; supports regulatory needs.

Growth and Expansion

  • Acquired Asteria Health in 2024 to control hormone compounding supply chain.
  • Bought assets from Simpatra and BioSana in 2024 to expand technology and product offerings.
  • Launched e-commerce and Amazon supplement sales in 2024 to reach more patients directly.
  • Added 850 new clinics in 2025, expanding its practitioner network across the U.S.
  • Restructured workforce in 2025 to improve operational efficiency.

What Makes biote Stand Out

biote’s all-cash revenue model reduces insurance risk for clinics. Its proprietary software and training create a strong practitioner network. Vertical integration through acquisitions helps control costs and supply chain reliability.

Five Things You Need to Know

  • 2025 revenue was $192.2 million, down 2.5% from 2024.
  • Net income rose to $31.6 million in 2025, up from $0.05 million in 2024.
  • Over 9,200 certified practitioners in 5,300+ clinics as of December 2025.
  • Supplements made up 22% of 2025 revenue, mostly sold through clinics.
  • Cash position was $24.1 million at year-end 2025, with $103.1 million in term loans outstanding.

Bottom Line

biote has grown by expanding its clinic network and acquiring supply chain assets. The company balances product innovation with operational efficiency in a regulated healthcare market.

AI Generated • Apr 16, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

223

CEO

Bret Christensen, MBA

Website

www.biote.com

Headquarters

Irving, TX 75038, US

BTMD Financials

Key Financial Metrics (TTM)

Gross Margin

70.12%

Operating Margin

15.43%

Net Income Margin

8.29%

Return on Equity

-22.91%

Return on Capital

69.19%

Return on Assets

17.53%

Earnings Yield

19.31%

Dividend Yield

0.00%

Payout Ratio

9.22%

Stock Overview

Market Cap

$70.67MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

30.33M

Volume

20

Avg. Volume

278.08K

Financials (TTM)

Gross Profit

$131.93M

Operating Income

$29.03M

EBITDA

$37.29M

Operating Cash Flow

$32.63M

Capital Expenditure

-$4.74M

Free Cash Flow

$27.89M

Cash & ST Invst.

$5.32M

Total Debt

$108.42M

Biote Performance Analysis

Biote annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 164,957,00018.3%
20232023-12-31USD 185,360,00012.4%
20242024-12-31USD 197,191,0006.4%
20252025-12-31USD 192,219,000-2.5%
Biote sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-0.3%
Q32025-09-30-1.9%
Q42025-12-31-3.2%
Q12026-03-31-3.2%
Biote annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -0.12-86.2%
20232023-12-31USD 0.13N/A
20242024-12-31USD 0.09-28.6%
20252025-12-31USD 0.74700.9%
Biote sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-73.0%
Q32025-09-30120.0%
Q42025-12-31-71.2%
Q12026-03-31-0.2%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$44.94M

-8.3%

Gross Profit

$30.95M

-14.9%

Gross Margin

68.88%

N/A

Market Cap

$70.67MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$316.92K

N/A

Employees

223

N/A

Net Income

$2.28M

-83.4%

EBITDA

$6.29M

-70.4%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$5.32M

-87.2%

Total Debt

$108.42M

-0.9%

Accounts Receivable

$7.40M

-4.7%

Inventory

$19.88M

+47.8%

Long Term Debt

$101.56M

-1.0%

Short Term Debt

$6.86M

+1.0%

Return on Assets

17.53%

N/A

Return on Invested Capital

47.74%

N/A

Free Cash Flow

$2.73M

-43.5%

Operating Cash Flow

$3.90M

-39.7%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
SPROSpero Therapeutics, Inc.
$1.18-0.00%
SCLXScilex Holding Company
$6.82-2.99%
INOInovio Pharmaceuticals, Inc.
$0.97+0.06%
LUCDLucid Diagnostics Inc.
$0.91+0.37%

Trending Stocks

Symbol / CompanyPricePrice Chg
NOKNokia
$8.70-0.06%
TQQQProShares Trust - ProShares UltraPro Qqq
$60.06-0.05%
SQQQProShares Trust - ProShares UltraPro Short Qqq
$47.62+0.05%
INLFInlif
$5.61+0.71%

Questions About BTMD

What is the current price of Biote?

Biote is trading at $2.34 per share.

What is the 52-week range for Biote?

Over the past 52 weeks, Biote has traded between $1.27 and $4.75.

How much debt does Biote have?

As of the most recent reporting period, Biote reported total debt of $108.42M.

How much cash does Biote have on hand?

Biote reported $5.32M in cash and cash equivalents in its most recent financial results.

What is Biote’s dividend yield?

Biote does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services